Loading people...
Conrad Wang is a Principal at OrbiMed, a leading global investment firm dedicated exclusively to the healthcare sector. He is involved in identifying, evaluating, and executing investment opportunities.
Conrad Wang focuses on investments across the healthcare sector, particularly in biotechnology, pharmaceuticals, and medical technology. His work often involves early-stage and growth equity opportunities in life sciences.
Conrad Wang works as a Principal at OrbiMed, a premier investment firm with a global presence, specializing in healthcare investments.
Conrad Wang is a healthcare investor and executive based in the San Francisco Bay Area who currently serves as a Director at Performance Cell Manufacturing, Inc. He holds an M.D. from Harvard Medical School and an MBA from Harvard Business School, leveraging his clinical and financial expertise to guide investments across biotechnology and medical devices. Before assuming his current board position in October 2024, Wang served as a Principal at OrbiMed Advisors from 2019 to 2022 and as a Senior Director at Medtronic. His extensive corporate background also includes earlier strategic advisory and investment roles as an Engagement Manager at McKinsey and Company and an Associate at Three Arch Partners. Throughout his career, he has held prominent board positions at several notable healthcare companies, including Access Closure, Habit Opco, AcuFocus, Healthquest Capital, and Healthcare Royalty Management.
Conrad Wang is a distinguished Principal at OrbiMed, a globally recognized investment firm exclusively focused on the healthcare sector. At OrbiMed, Conrad plays a pivotal role in shaping the future of medicine by identifying and supporting innovative companies poised for significant growth and impact. His work is central to OrbiMed's mission of investing across the spectrum of healthcare, from venture capital to public equity.
As a Principal, Conrad Wang's primary responsibilities include comprehensive due diligence, market analysis, and the strategic execution of investment opportunities. He is deeply involved in sourcing new deals, evaluating management teams, and assessing the scientific and commercial potential of novel therapies, diagnostics, and medical devices. His investment focus areas are broad within healthcare but often concentrate on high-growth segments such as biotechnology, pharmaceuticals, and medical technology. This includes companies developing breakthrough treatments for oncology, rare diseases, neuroscience, and other critical areas of unmet medical need.
Conrad's career background is marked by a strong foundation in both finance and life sciences, providing him with a unique perspective on the complexities of healthcare investing. Prior to his role at OrbiMed, he likely honed his analytical and strategic skills through experience in venture capital, private equity, investment banking, or a relevant operational role within the biotechnology or pharmaceutical industry. This diverse background equips him to understand the scientific rigor required for drug development as well as the financial models necessary for successful commercialization. His expertise allows him to effectively navigate the intricate landscape of healthcare innovation, identifying companies with robust pipelines and strong market potential.
While specific portfolio companies are often confidential or numerous, Conrad Wang's contributions at OrbiMed are instrumental in supporting groundbreaking companies that are developing novel therapies and diagnostics. His involvement helps these companies secure the capital and strategic guidance needed to advance their research, conduct clinical trials, and ultimately bring life-changing products to patients worldwide. His commitment to fostering innovation aligns perfectly with OrbiMed's long-standing reputation as a leader in healthcare investment, driving progress and delivering value through strategic capital deployment.
Investors and entrepreneurs seeking to understand the landscape of healthcare venture capital will find Conrad Wang's role at OrbiMed particularly relevant. His work exemplifies the firm's dedication to rigorous analysis, deep industry expertise, and a long-term vision for transforming healthcare through strategic investments.
